MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-14-2023
Adamis Pharmaceuticals Corporation Cash and Cash Equivalents 2011-2026 | ADMP
Annual Cash and Cash Equivalents Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.08 M | 23.2 M | 6.86 M | 8.81 M | 19.3 M | 17.3 M | 4.09 M | 4.08 M | 3.77 M | - | 7.52 K | 1.24 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.2 M | 7.52 K | 8.16 M |
Quarterly Cash and Cash Equivalents Adamis Pharmaceuticals Corporation
| 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.66 M | 3.1 M | 1.08 M | 2.42 M | 8.88 M | 17.8 M | 23.2 M | 28.7 M | 40.3 M | 57.6 M | 6.75 M | 6.75 M | 6.86 M | 6.86 M | 8.81 M | 8.81 M | 8.81 M | 8.81 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 17.3 M | 17.3 M | 17.3 M | 17.3 M | 4.09 M | 4.09 M | 4.09 M | 4.09 M | 4.08 M | 4.08 M | 4.08 M | 4.08 M | 3.77 M | 3.77 M | 2.13 M | 5.4 M | 4.67 M | 120 K | 3.4 M | - | 1.42 K | 10.1 K | 720 K | 7.52 K | 1.6 K | 3.03 K | 191 K | 1.24 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 57.6 M | 1.42 K | 9.32 M |
Cash and Cash Equivalents of other stocks in the Drug manufacturers industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
5.89 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
2.56 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
12.1 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
37.2 M | - | - | $ 754 M | USA |
 |
DURECT Corporation
DRRX
|
28.4 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
55.3 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
778 M | - | - | $ 28.9 M |  Irlanda |
 |
Harrow Health
HROW
|
72.9 M | $ 40.94 | 1.01 % | $ 1.5 B | USA |
 |
Catalent
CTLT
|
289 M | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
30.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
18 M | $ 4.26 | 1.58 % | $ 59.9 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
51.4 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
2.28 M | - | - | $ 33.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
956 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
83.2 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Pacira BioSciences
PCRX
|
277 M | $ 24.22 | -4.98 % | $ 1.12 B | USA |
 |
Solid Biosciences
SLDB
|
59.9 M | $ 7.13 | -1.79 % | $ 624 M | USA |
 |
Evoke Pharma
EVOK
|
4.74 M | - | - | $ 36.6 M | USA |
 |
Bausch Health Companies
BHC
|
947 M | $ 5.69 | -0.61 % | $ 2.08 B | Canada |
 |
Canopy Growth Corporation
CGC
|
114 M | $ 1.13 | 1.35 % | $ 122 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
5.37 M | $ 1.2 | 9.18 % | $ 1.49 M | USA |
 |
Aurora Cannabis
ACB
|
138 M | $ 3.47 | 0.73 % | $ 86.3 M | Canada |
 |
Tilray
TLRY
|
207 M | $ 6.18 | -1.04 % | $ 3.82 B | Canada |
 |
Lannett Company
LCI
|
87.9 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
24.6 M | $ 1.41 | 0.01 % | $ 402 M | Canada |
 |
Veru
VERU
|
24.9 M | $ 2.26 | 0.44 % | $ 305 M | USA |
 |
Evolus
EOLS
|
53.8 M | $ 5.32 | -1.3 % | $ 343 M | USA |
 |
Sundial Growers
SNDL
|
252 M | $ 1.4 | 2.57 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
112 M | $ 8.5 | 3.03 % | $ 435 M | USA |
 |
Organogenesis Holdings
ORGO
|
136 M | $ 2.56 | 8.72 % | $ 337 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
104 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
2.45 M | $ 0.82 | -6.19 % | $ 3.54 M | USA |
 |
ProPhase Labs
PRPH
|
9.11 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
112 M | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
10.2 M | $ 18.49 | 0.33 % | $ 118 M | USA |
 |
PetIQ
PETQ
|
116 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
3.5 M | $ 7.68 | 2.13 % | $ 303 M | USA |
 |
Recro Pharma
REPH
|
8.1 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
73.7 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
21.3 M | $ 1.0 | 7.52 % | $ 49.9 M | USA |
 |
PLx Pharma
PLXP
|
69.4 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
992 M | $ 15.03 | 0.57 % | $ 18 B | USA |
 |
Zomedica Corp.
ZOM
|
9.02 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
50.6 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
10.7 M | $ 0.88 | 0.5 % | $ 31.7 M | USA |
 |
Tricida
TCDA
|
21.1 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
345 K | $ 0.53 | -2.37 % | $ 2.27 M |  China |
 |
TherapeuticsMD
TXMD
|
7.48 M | $ 2.04 | 0.24 % | $ 23.6 M | USA |